# Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis

> **NCT00012467** · PHASE2 · COMPLETED · sponsor: **InterMune** · enrollment: 60 (—)

## Conditions studied

- Meningitis, Cryptococcal
- HIV Infections

## Interventions

- **DRUG:** Itraconazole
- **DRUG:** Flucytosine
- **DRUG:** Fluconazole
- **DRUG:** Amphotericin B
- **DRUG:** Interferon gamma-1b

## Key facts

- **NCT ID:** NCT00012467
- **Lead sponsor:** InterMune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** —
- **Final completion:** 2001-07
- **Target enrollment:** 60 (—)
- **Last updated:** 2009-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00012467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00012467, "Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00012467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*